NASDAQ · TSHA
Healthcare · Biotechnology
$5.06
Up+$0.00 (+0.09%)
Updated Sep 16, 2026, 5:22 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TSHA closed at $5.06 after 20 trading sessions, down 18.26% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $5.00 | $5.19 | $4.90 | $5.06 | 5.15M |
| Sep 14, 2026 | $5.00 | $5.12 | $4.98 | $5.01 | 6.7M |
| Sep 11, 2026 | $5.26 | $5.28 | $4.98 | $5.02 | 1.78M |
| Sep 10, 2026 | $5.24 | $5.24 | $5.01 | $5.16 | 2.4M |
| Sep 9, 2026 | $5.40 | $5.485 | $5.285 | $5.34 | 1.81M |
| Sep 8, 2026 | $5.57 | $5.575 | $5.40 | $5.48 | 2.22M |
| Sep 4, 2026 | $5.52 | $5.61 | $5.42 | $5.60 | 2.11M |
| Sep 3, 2026 | $5.62 | $5.665 | $5.50 | $5.57 | 1.88M |
| Sep 2, 2026 | $5.73 | $5.96 | $5.55 | $5.64 | 1.99M |
| Sep 1, 2026 | $5.645 | $5.77 | $5.56 | $5.70 | 1.76M |
| Aug 31, 2026 | $5.70 | $5.775 | $5.535 | $5.69 | 2.06M |
| Aug 28, 2026 | $5.89 | $5.915 | $5.625 | $5.77 | 2.07M |
| Aug 27, 2026 | $5.99 | $6.09 | $5.8902 | $5.96 | 2.19M |
| Aug 26, 2026 | $6.15 | $6.27 | $5.91 | $6.02 | 1.28M |
| Aug 25, 2026 | $5.99 | $6.27 | $5.99 | $6.20 | 1.69M |
| Aug 24, 2026 | $6.02 | $6.075 | $5.825 | $5.97 | 2.59M |
| Aug 21, 2026 | $6.18 | $6.24 | $6.015 | $6.09 | 2.83M |
| Aug 20, 2026 | $6.04 | $6.30 | $5.92 | $6.11 | 3.4M |
| Aug 19, 2026 | $6.40 | $6.52 | $6.29 | $6.43 | 4.28M |
| Aug 18, 2026 | $6.08 | $6.275 | $6.03 | $6.19 | 1.63M |
The latest Smart Investors Daily articles mentioning TSHA.
TSHA research
Company profile and research snapshot.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | Goldman Sachs | Buy | — |
| Jul 2, 2026 | Citizens | Market Outperform | — |
| Jun 30, 2026 | Baird | Outperform | — |
| Jun 30, 2026 | Needham | Buy | — |
| Jun 23, 2026 | BMO Capital | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 11, 2026
Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and execution for TSHA-102. See why TSHA stock is a buy.
Yahoo · Sep 4, 2026
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common s
Yahoo · Aug 13, 2026
Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response rate in early TSHA-102 Rett syndrome trial data, expanding its Catalent manufacturing agreement, and outlining cash coverage into late 2028. See our latest analysis for Taysha Gene Therapies. Taysha Gene Therapies has seen its share price move around these updates, with a 19.05% 30 day share price return and a very large 1 year total shareholder return, while the 5 year total shareholder return...
Yahoo · Aug 12, 2026
Moby summary of Taysha Gene Therapies, Inc.'s Q2 2026 earnings call
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TSHA.
